Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin dose-response study in pediatric cerebral palsy spasticity
2012-005496-14Phase 3Completed
- Sponsor
- Merz
- Start
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of botulinum toxin type A in cerebral palsy (CP), spastic paresis, sponsored by Merz. Started Jan 2016; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
cerebral palsy (CP)spastic paresis
Beyond the preview
Go deeper on 2012-005496-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005496-14.